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Abstract
Dendritic cell (DC) defects are an important component
of immunosuppression in cancer. Here, we assessed
whether cancer could affect circulating DC populations
and its correlation with tumor progression. The blood
DC compartment was evaluated in 136 patients with
breast cancer, prostate cancer, and malignant glioma.
Phenotypic, quantitative, and functional analyses were
performed at various stages of disease. Patients had
significantly fewer circulating myeloid (CD11c+) and
plasmacytoid (CD123+) DC, and a concurrent accumu-
lation of CD11cCD123 immature cells that expressed
high levels ofHLA-DR+ immature cells (DR+IC). Although
DR+IC exhibited a limited expression of markers as-
cribed to mature hematopoietic lineages, expression of
HLA-DR, CD40, and CD86 suggested a role as antigen-
presenting cells. Nevertheless, DR+IC had reduced ca-
pacity to capture antigens and elicited poor proliferation
and interferon-; secretion by T-lymphocytes. Im-
portantly, increased numbers of DR+IC correlated with
disease status. Patients with metastatic breast cancer
showed a larger number of DR+IC in the circulation
than patients with local/nodal disease. Similarly, in pa-
tientswith fully resected glioma, the proportion of DR+IC
in the blood increased when evaluation indicated tumor
recurrence. Reduction of blood DC correlating with ac-
cumulation of a population of immature cells with poor
immunologic functionmaybe associatedwith increased
immunodeficiency observed in cancer.
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Keywords: Solid tumors, dendritic cell subsets, immune dysfunction,
immature antigen-presenting cell, breast cancer.
Introduction
Generation of anticancer immunity requires antigen-
presenting cells (APC) that recognize tumors, and process
and present antigens to T-lymphocytes, which subsequently
target malignant cells [1]. Dendritic cells (DC) are the key APC
population for initiating and coordinating antitumor responses
[1,2]. Despite the potential for tumor control, the immune
system often fails. Numerous mechanisms, including deletion
of tumor-specific cytotoxic T-lymphocytes [3] and recruitment of
regulatory T-lymphocytes [4] and inhibitory cell types [5], have
been implicated in this failure. It has also been suggested that a
tumor’s incapacity to recruit DC significantly contributes to im-
mune evasion [6–8].
More recently, the suppressive effects of tumors on DC ma-
turation and differentiation have been reported to play a crucial
role in the systemic failure of the host to mount an effective
antitumor response [9–11]. Several tumor-derived factors [vas-
cular endothelial growth factor (VEGF), interleukin (IL) 6, macro-
phage colony-stimulating factor (M-CSF), gangliosides,
prostanoids, and polyamines] affect DC differentiation from
progenitors, both in vitro and in vivo [12–18]. This is consistent
with the fact that reduced DC counts are frequently found
in the peripheral blood of cancer patients [13,16,19,20]. A re-
view of the effects of tumor-derived factors on DC was re-
cently compiled [21].
In spite of this evidence, only a few studies have directly
assessed the functional status of DC populations circulating
in vivo in patients with cancer [8,13,16,22]. Circulating blood
DC can be identified as mononuclear cells expressing major
histocompatibility complex (MHC) II molecules (HLA-DR) but
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lacking common lineage markers (Lin) such as CD3, CD14,
CD19, CD20, CD56, and CD34 [23]. This blood DC com-
partment (LinHLA-DR+ cells) includes two different subsets
that are discernible into myeloid or plasmacytoid DC based
on their reciprocal expression of CD11c (a-integrin) and
CD123 (IL-3 receptor a) [24].
The aim of this study was to assess the blood DC com-
partment in patients with cancer to ascertain whether alter-
ations in DC subset distribution could correlate with tumor
progression. For this purpose, we analyzed a large cohort
of patients with different types of cancer (including breast
cancer, prostate cancer, and malignant glioma) at various
stages of disease. A 12-week chronological monitoring was
also performed in patients with malignant glioma to relate any
changes in the composition of the blood DC compartment
with tumor recurrence in individual patients. Our results indi-
cate that, in contrast to healthy donors, patients with cancer
demonstrate a marked alteration in the distribution of myeloid
(CD11c+DC) and plasmacytoid (CD123+DC) subtypes with a
significant accumulation of CD11cCD123 immature cells.
Notably, accumulation of these immature cells with poor APC
function correlates with disease status and tumor growth.
These findings may prove to be relevant in understanding
DC pathophysiology in cancer progression.
Materials and Methods
Patients and Donors
A total of 120 female patients (43–80 years of age) with
histologically confirmed breast adenocarcinoma were en-
rolled in the study. Of these, 96 patients presented with early
disease, either local (stage I [T1N0M0]: tumor < 2 cm [T1], no
lymph node involvement [N0], and no distant metastases
[M0]; n = 37) or nodal (stage II [T2N1M0]: tumor between 2
and 5 cm [T2], ipsilateral lymph node involvement [N0–N1],
and no distant metastases [M0]; n = 59), and 24 patients
presentedwith advancedmetastatic disease (stage IV [TNM1]:
any tumor size/node involvement with distant metastases
to other organs [M1]). All patients were newly diagnosed,
except for those with advanced disease who presented
with recurrence after a disease-free interval and had no prior
therapy for at least 6 months. Staging was performed in
accordance with International Union Against Cancer: TNM
Classification of Malignant Tumors [25]. In addition, 10 male
patients (68–80 years of age) with histologically confirmed
prostate cancer were enrolled in the study. All patients had
hormone-refractory tumors with elevated and rising prostate-
specific antigen (PSA) levels on at least two consecutive
occasions, ranging from 11 to 890 ng/ml, in the presence of
castrate serum testosterone levels. Although the Interna-
tional Union Against Cancer system does not have a clear
category for the first seven patients who had consistently
rising serum PSA values (all > 4 ng/ml) in the absence of bone
or soft tissuemetastases, the conditions of the remaining three
patients were classified as stage IV ([TNM1]: any tumor size/
node involvement with distant metastases to other organs
[M1]). Of these, one patient had multiple soft tissue secondary
deposits and two had bone metastases. Three patients had
someof their soft tissue tumormaterials harvested as a source
of antigens in a vaccine study. In addition, a total of six patients
(three females and three males, 26–68 years of age) with
newly diagnosed supratentorial high-grade malignant glioma
(grade IV) were enrolled in the study. Grading was performed
in accordance with the World Health Organization Classifi-
cation of Tumors: Pathology and Genetics of Tumors of the
Nervous System [26]. For the follow-up study, glioma patients
who were initially treated and underwent complete macro-
scopic resection were monitored. Blood samples were col-
lected starting at 4 weeks and then at 6, 8, and 12 (24) weeks
after tumor resection. To assess tumor recurrence, each pa-
tient underwent computed tomography (CT) and/or magnetic
resonance imaging (MRI) of the brain and comprehensive
clinical examination at 4, 6, 8, and 12 (24) weeks postsurgery.
According to uniform clinical protocols, two patients received
symptomatic management with phenytoin and diazepam
during the follow-up period. One patient received temozol-
amide and two underwent additional surgical excision of tumor
recurrence after the follow-up period. Finally, 20 healthy
donors (12 females and 8 males, 22–73 years of age)
volunteered for the study and served as controls. For pheno-
typic and cell sorting experiments, 50 or 350 ml of venous
blood was collected into heparinized tubes and processed
immediately. The research ethics committees of both clinical
(Wesley Medical Centre, Royal Brisbane and Women Hos-
pital andMaterMisericordiae Hospital) and scientific (Queens-
land Institute of Medical Research) institutions approved the
study protocols.
Monoclonal Antibodies, Reagents, and Cytokines
The following monoclonal antibodies were used in this
study: CD3, CD14, CD19, CD20, CD56, CD34, CD2, CD4,
CD33, CD7, CD11c, HLA-DR, CD15, CD127, CD123, CD80,
CD86, DC-SIGN, and IgG1, IgG2a, and IgG2b isotype con-
trols from BD Pharmingen (BD Biosciences, San Jose, CA);
CD62L, CD4, HLA-DR, CD40, CD83, CD19, and IgG1 iso-
type control from Beckman Coulter (Fullerton, CA); and
BDCA-2, BDCA-3, BDCA-4, and CD1c from Miltenyi Biotech
(Bergisch Gladbach, Germany). CD10, CD79a, CD11b,
CD13, myeloperoxidase (MPO), CD41, CD61, CD235a,
and CD71 (all from BD Biosciences) and SIgE, SIgn, and
Cm (all from DakoCytomation, Fort Collins, CO) were kindly
provided by Dr. Greg Bryson (Royal Brisbane Hospital, Bris-
bane, Australia). Fluorescein isothiocyanate (FITC)–, PE-,
biotin-, APC-, or PE-Cy5–conjugated antibodies were used.
For indirect staining with biotinylated antibodies, streptavidin
APC (BD Biosciences) was used. For exclusion of dead cells,
samples were stained with 7-amino-actinomycin D (7-AAD;
BD Biosciences). Tetanus toxoid (TT) obtained from CSL
(Melbourne, Victoria, Australia) was conjugated with FITC
(FITC–TT) in 0.5 M bicarbonate buffer (pH 9.5) and dialyzed
in phosphate-buffered saline (PBS) for 48 hours before use.
Dialysis membranes (membra cell; Polylabo, Strasbourg,
France) with aMw cutoff of under 10,000 to 14,000 were used.
Sheep red bloodcellswereobtained fromEquicell (Melbourne,
Victoria, Australia). Complete media included RPMI 1640
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supplemented with 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 mg/ml), L-glutamine (2 mM), HEPES (25
mM), and nonessential amino acids (all purchased fromGibco
Life Technologies, Gaithersburg, MD). The combination of
proinflammatory cytokines [27] consisted of IL-1b (10 ng/ml),
IL-6 (10 ng/ml), and TNF-a (10 ng/ml) (all obtained from R&D
Systems, Minneapolis, MN) plus prostaglandin E2 (PGE2;
1 mg/ml; Sigma, St. Louis, MO). The CpG oligodeoxynucleo-
tide 2216 (CpG ODN; 3 mg/ml) [28] was acquired from Gene-
works (Melbourne, Victoria, Australia). Lipopolysaccharide
(LPS; 50 ng/ml) and double-stranded RNA (poly I:C; 50 mg/ml)
[29] were purchased from Sigma.
Cell Purification and Microscopy
DC and DR+IC were purified from peripheral blood mono-
nuclear cells (PBMC). Briefly, PBMC from patients with
breast cancer were stained with lineage mixture (CD3,
CD14, CD19, CD20 and CD56) and CD34 (all FITC), HLA-
DR (PE), and CD11c (APC), and then indirectly stained with
biotinylated CD123 followed by streptavidin (APC). CD34
was added to the lineage mixture (Lin) to exclude circulating
hematopoietic stem cells. 7-AAD was used as a viability
indicator. Viable DC (LinHLA-DR+CD11c+CD123+) and
DR+IC (LinHLA-DR+CD11cCD123) were sorted in paral-
lel (99% purity) usingMoFlo Sorter (DakoCytomation) and re-
suspended in complete medium. For light microscopy (LM),
cytospins were made by preparing 2  104 to 3  104 sorted
cells onto a glass slide. Cytospins were air-dried and stained
using May–Grunwald–Giemsa. For electron microscopy
(EM), 2  104 to 3  104 sorted cells were fixed in 3% glu-
taraldehyde and 4% paraformaldehyde plus 0.8% calcium
chloride before being embedded in epoxy resin. Ultrathin
sections were cut and stained for EM.
Phenotype, Antigen Uptake, and Cell Counts
Four-color flow cytometry was used to analyze the pheno-
type and antigen uptake of DC and DR+IC in PBMC. For
phenotypic analyses, cells were stained with the lineage mix-
ture (FITC), HLA-DR (PE-Cy5), CD11c, CD123 (APC), and
antigen of interest (PE). For phenotypic maturation, PBMC
were cultured (107 cells/ml) in six-well plates for 18 to 36 hours
in complete medium in the presence of a combination of in-
flammatory cytokines (IL-1b, IL-6, andTNF-a plusPGE2;Cyto-
kine Cocktail [CC]), LPS, poly I:C, or CpG ODN. Cells were
stained with the lineage mixture (FITC), HLA-DR (PE-Cy5),
CD11c, andCD123 (APC) andCD40, CD80, CD83, andCD86
(PE). Doses and incubation times were optimized in prelimi-
nary experiments. For antigen uptake, PBMC were analyzed
fresh or after activation with poly I:C or CC. Following activa-
tion, cells were resuspended in complete medium for incuba-
tion (60 minutes) with FITC–TT (0.5 mg/ml) at either 4jC or
37jC. Cells were washed four times in cold PBS and then
stained. Antigen capture was calculated as the difference in
mean fluorescence intensity (DMFI) between the test (37jC)
and the control (4jC). In all experiments, 5  105 to 10  105
events were collected within the mononuclear cell gate.
Where indicated, absolute counts (106 l1) were calculated
from the number of PBMC estimated by the automated cell
counter (Advia 120, Hematology System or Technicon H.3
RTX; Bayer, Tarrytown, NY) multiplied by the percentage
of DR+IC, CD11c+DC, and CD123+DC, as determined by
fluorescence-activated cell sorter (FACS) analysis. Data were
acquired on a FACS Calibur flow cytometer and analyzed
using CellQuest 3.1 (BD Biosciences), FloJo (TreeStar, San
Carlos, CA), or Summit (Cytomation) software.
Mixed Lymphocyte Reaction (MLR) and Interferon
(IFN) g Secretion
The capacity of DC and DR+IC to stimulate allogeneic
T-cell proliferation was tested in MLR. Allogeneic T-cells
were obtained by rosetting PBMC with neuraminidase-
treated sheep red blood cells (z 90% CD3+ cells). DC and
DR+IC were purified from patients with breast cancer using
MoFlo Sorter, as described above. Varying numbers of DC
and DR+IC were cultured (37jC, 5% CO2) in triplicate with
105 allogeneic T-cells for 5 days in complete medium.
Sixteen hours prior to harvesting, 1 mCi/well [3H]thymidine
was added to each well. [3H]thymidine incorporation was
measured in a b-scintillation counter (MicroBeta Trilux Scin-
tillation Counter; Wallac, Turku, Finland). For measurements
of IFN-g secretion, after 5 days in culture, supernatants
were collected, pooled, and assayed using IFN-g ELISA kit
(Mabtech, Stockholm, Sweden), according to the manufac-
turer’s instructions.
Statistical Analysis
Comparisons of samples for the establishment of statisti-
cal significance were determined by two-tailed Student’s t
test. Results were considered to be statistically significant
when P < .05.
Results
Blood DC Subset Composition in Cancer
The blood DC compartment (LinHLA-DR+ population)
(Figure 1A) includes two different DC subsets that can be
distinguished into myeloid and plasmacytoid lineages based
on their reciprocal expression of CD11c and CD123 antigens
[24]. Given that dissimilar alterations in the frequency of
these subsets have been reported in patients with cancer
[16,20], we set out to carefully analyze the CD11c+DC and
CD123+DC subset compositions of the blood DC compart-
ment in a cohort of 34 patients with different types of solid
tumors. We assessed patients with breast cancer (stage II;
n = 18), malignant glioma (grade IV; n = 6), and hormone-
refractory prostate cancer (n = 10). In addition, 11 age-
matched healthy donors served as controls (Figure 1B). In
healthy donors, the proportion of CD11c+DC (46.6 ± 7.4%)
and CD123+DC (36.9 ± 6.6%) accounted for 83.5 ± 1.7% of
the total blood DC compartment. In contrast, in patients
with breast cancer, both DC subtypes accounted for 67.9 ±
3.1% (CD11c+DC: 46.0 ± 4.2% and CD123+DC: 21.9 ±
2.8%); in malignant glioma, both DC subtypes accounted
for 67.9 ± 3.6% (CD11c+DC: 35.8 ± 3.8% and CD123+DC:
32.1 ± 3.9%); and in prostate cancer, both DC subtypes
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accounted for 65.7 ± 3.9% (CD11c+DC: 29.0 ± 4.5% and
CD123+DC: 36.7 ± 5.0%) of the total blood DC compartment.
As shown in Figure 1B, this finding points to the existence of
a significant population of CD11cCD123 cells expressing
high levels of HLA-DR and lacking markers for mature
hematopoietic lineages (HLA-DR+ immature cells, DR+IC).
Interestingly, although this population represented only
16.4 ± 1.7% of the blood DC compartment in healthy donors,
it represented a significantly larger proportion in patients with
breast cancer (31.2 ± 3.1%), glioma (32.0 ± 3.6%), and
prostate cancer (34.2 ± 3.9%; Figure 1C). These results
were further confirmed when a second cohort of 35 patients
with breast cancer was assessed (CD11c+DC: 44.0 ± 3.6%,
CD123+DC: 24.5 ± 2.9%, and DR+IC: 31.4 ± 4.6%). Inter-
estingly, when these patients were grouped according
to stage of disease (stage I, n = 17; stage II, n = 10; and
stage IV, n = 8), analysis revealed that the DR+IC population
represented 18.1 ± 4.3% of the blood DC compartment in
patients with local disease (stage I), 28.3 ± 8.3% in patients
with nodal disease (stage II), and 63.5 ± 7.0% in patients with
metastatic disease (stage IV), suggesting an association
with disease extension (Figure 2A).
Correlation with Tumor Burden
Given that our data demonstrated a larger increment in the
proportion of DR+IC in patients with advanced breast cancer,
we set out to assess whether numeric changes could corre-
late with status of disease. To test this, we estimated the
absolute numbers of circulating DR+IC in the peripheral blood
of 28 patients with breast cancer, and we subsequently
analyzed their distribution according to the stage of disease
(stage I, n = 10; stage II, n = 10; and stage IV, n = 8).We found
that although the absolute numbers of DR+IC were compa-
rable in healthy donors and early-disease patients, DR+IC
counts were significantly increased in patients with advanced
Figure 1. DC subset composition in cancer. (A) The blood DC compartment (LinHLA-DR+ cells) in PBMC can be further separated (B) based on the expression of
CD11c ( y axis) and CD123 (x axis) into myeloid (CD11c+DC) and plasmacytoid (CD123+DC) subtypes and a minor population of CD11cCD123 cells (DR+IC). In
patients with cancer, this population can be significantly increased. (C) The composition of the blood DC compartment was analyzed to determine the proportion of
CD11c+DC (black), CD123+DC (grey), and DR+IC (clear) in a cohort of healthy donors (n = 11) and patients with cancer, including breast cancer (stage II, n = 18),
glioma (grade IV, n = 6), and prostate cancer (n = 10). Error bars indicate SEM. Statistically significant differences are indicated (***P < .001).
Figure 2. Correlation with disease status. (A) In a cohort of 35 patients with
breast cancer (stage I, n = 17; stage II, n = 10; and stage IV, n = 8) and
11 healthy donors, the composition of the blood DC compartment was
analyzed to determine the proportion of CD11c+DC (black), CD123+DC
(grey), and DR+IC (clear) according to the stage of disease. (B–D) In a
cohort of 28 patients with breast cancer (stage I, n = 10; stage II, n = 10; and
stage IV, n = 8) and 11 healthy donors, absolute numbers of (B) DR+IC, (C)
CD11c+DC, and (D) CD123+DC were quantified from the number of PBMC
(106 l1) in the blood, determined by a hematology cell counter, multiplied by
the percentage of cells determined by FACS, and plotted according to the
stage of disease. Means are shown as horizontal lines. Statistically significant
differences are indicated (*P < .05; **P < .01; ***P < .001).
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disease (Figure 2B). This is in keeping with the alteration in
the percentage of DR+IC estimated as a proportion of the
blood DC compartment (healthy: 16.4 ± 1.7%; stage I: 16.4 ±
6.1%; stage II: 22.0 ± 9.2%; and stage IV: 65.7 ± 6.4%). In
contrast to DR+IC, the absolute numbers of CD11c+DC and
CD123+DC in patients with advanced disease were signifi-
cantly reduced when compared to those of healthy donors
and early-disease patients (Figure 2, C and D), confirming
that accumulation of DR+IC coincides with a reduction in the
number of competent CD11c+DC and CD123+DC.
We also assessed whether accumulation of DR+IC could
correlate with tumor burden in individual patients. For this
purpose, tumor progression was assessed in a cohort of
six patients with completely resected high-grade malignant
glioma. Given that systemic metastases of primary cerebral
malignant gliomas are very rare, accounting for less than
0.5% of cases [30], accurate estimation of tumor burden in
individual patients is possible by carefully monitoring disease
status within the central nervous system. Patients were
monitored for clinical and radiological signs of tumor recur-
rence (CTandMRI) at 4, 6, 8, and 12 (24) weeks after surgical
excision (Figure 3, A and B). Tumor burden was estimated as
the sum of the maximum perpendicular diameters (x, y, z)
registered for each lesion. Each lesion was monitored at the
same anatomic level throughout the follow-up period. In par-
allel, the frequency of DR+IC as a percentage of the blood
DC compartment was estimated. Repeated measurements
performed on eight samples from six patients demonstrated
a small variation (< 16.2%, with an average of 9.2%) on
these estimates. Cumulatively, our data demonstrated that
the increase in DR+IC in the circulation correlated with
recurrence and enlargement of tumor lesions on follow-up.
Indeed, when clinical and imaging evaluation demonstrated
tumor progression, the proportion of DR+IC increased in the
peripheral blood (Figure 3, A and B).
Morphology and Costimulatory Phenotype
DC are heterogeneous and encompass populations with
different morphologies, phenotypes, and properties. Given
that DR+IC represented a significant proportion of the blood
DC compartment in cancer patients, we analyzed their mor-
phology and costimulatory phenotype by carrying out com-
parisons with their DC counterparts. PBMCwere isolated from
patients with breast cancer (stage II, n = 3), and LinHLA-DR+
cells (Figure 1A) were separated into DC (CD11c+CD123+)
and DR+IC (CD11cCD123) based on the expression of
CD11c and CD123 (Figure 4A). Each population was exam-
ined by LM (May–Grunwald–Giemsa staining) and EM.
Freshly isolated DC were relatively large cells (7–8 mm diam-
eter) featuring an irregular surface with abundant cytoplasm
and veiled projections (Figure 4B; DC and LM). At an ultra-
structural level, several cytoplasmic organelles (i.e., mitochon-
dria and smooth endoplasmic reticulum) and ribosomes were
evident. The nucleus was lobulated or indented and mainly
euchromatic (Figure 4B; DC and EM). In contrast, DR+ICwere
smaller cells (4–5 mm diameter) showing a relatively irregular
surface with some projections and a large, rounded hetero-
chromatic nucleus (Figure 4B; DR+IC and LM). The volume of
Figure 3. Correlation with tumor burden. (A) The percentage of DR+IC within the blood DC compartment ( y axis, left) was analyzed in a group of patients with fully
resected malignant glioma starting at 4 weeks and then at 6, 8, and 12 (24) weeks after surgery (x axis). Each patient underwent CT and/or MRI of the brain and
comprehensive clinical examination to determine tumor progression. Tumor burden ( y axis, right) was estimated as the sum of the maximum perpendicular
diameters (x, y, z) registered for any given lesion detected at the time of evaluation. When multiple lesions were present, sizes were added. Results shown
correspond to four patients, representative of six patients who were assessed. (B) Longitudinal MRI follow-up corresponds to ‘‘patient 02’’ (shown above),
indicating tumor progression. Arrows point to recurring lesion(s), and numbers indicate time points of assessment (weeks postsurgery). Means are shown as
horizontal lines. Statistically significant differences are indicated (*P < .05).
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the cytoplasm compared with that of the nucleus was small.
The cytoplasm had fewer inclusions and organelles than
DC. The relative absence of organelles, the scanty cytoplasm,
and the largely condensed chromatin in the nucleus sug-
gested a more immature cell compared to DC (Figure 4B;
DR+IC and EM). Given that the expression of HLA-DR and
other costimulatory molecules such as CD40, CD80, CD83, or
CD86 is known to reflect the maturation status of APC, we
assessed their expression in DR+IC. As shown in Figure 4C,
these cells revealed a low expression of CD80 (< 1%) and
CD83 (< 1%), a moderate expression of CD86 (15%), and a
high expression of CD40 (50%) and HLA-DR (100%). No-
tably, these data are consistent with an evaluation of CD40
expression in the blood DC compartment (encompassing DC
and DR+IC) of 41 patients with breast cancer (stage I, n = 20;
stage II, n = 12; and stage IV, n = 9). Patients with advanced
disease had significantly increased CD40 expression (intensity
and percentage; Figure 4D) and concomitantly the largest pro-
portion of circulating DR+IC (Figure 2A).
Ability to Capture and Present Antigens to T-cells
The expression of HLA-DR and costimulatory molecules
indicated a potential role of DR+IC as APC. To test this
possibility, we set out to assess their capacity to capture and
present antigen, and to induce T-cell activation. First, we
studied the ability of DR+IC isolated from patients with breast
cancer (stage II, n=5) to capture a soluble antigen (FITC–TT).
In fresh samples, DC had a higher capacity to take up anti-
gens (DMFI: 61.2 ± 8.7) compared to DR+IC (DMFI: 9.4 ± 2.2)
(P < .05; Figure 5A). Given that DCare known to downregulate
their capacity to capture antigens on activation [31], we also
assessed whether DR+IC could modulate their FITC–TT up-
take in response to exogenous stimuli. Two classes of inflam-
matory mediators known to activate DC [29] were tested: 1) a
combination of inflammatory cytokines (TNF-a, IL-1b, IL-6,
and PGE2; CC) [27] and 2) synthetic double-stranded RNA
(poly I:C). We found that stimulated DC exhibited a small (not
significant) reduction in antigen capture compared to un-
stimulated cells (Figure 5B). As with DC, DR+IC down-
regulated this capacity (Figure 5B), suggesting a certain
level of functional modulation. We then assessed the ability
of DR+IC to present antigens and to induce the proliferation
of alloreactive T-cells. We found that DR+IC purified from
patients with breast cancer (stage II, n = 5) induced a signifi-
cantly reduced (P < .05) proliferation of allogeneic T-cells in
MLR compared to DC (Figure 5C). Finally, we examined the
capacity of DR+IC to induce IFN-g secretion in allogeneic
T-cells. We found that DR+IC purified from cancer patients
(stage II, n = 5) were poor stimulators of IFN-g secretion.
Conversely, DC induced significantly (P< .001) higher levels of
IFN-g secretion by T-cells (Figure 5D).
Response to Inflammatory Factors
Another feature of APC is their capacity to mature and
respond to activation signals. As with antigen uptake, this
ability is regulated by different types of inflammatory media-
tors [32]. Therefore, we assessed the phenotypic maturation
ofDR+IC andDC in response to a range of 1) proinflammatory
mediators (CC) and 2) pathogen-derived factors, including
ligands for toll-like receptors 4 (LPS), 3 (poly I:C), and 9
Figure 4. Morphology and phenotype. (A) The blood DC compartment was separated into DC (CD11c+CD123+) or DR+IC (CD11cCD123) based on the
expression of CD11c and CD123 ( y axis). Viable cells (7-AAD; x axis) were sort-purified. (B) DC and DR+IC were analyzed by LM (left panel) and EM (right
panel). Size bars represent 1 m. Micrographs shown are representative of three breast cancer patients (stage II) who were assessed. (C) PBMC purified from
patients with cancer were separated into DC or DR+IC ( y axis), and the percentage of cells positive (x axis) for CD80, CD86, CD83 CD40, and HLA-DR was
determined. Results shown are representative of 17 breast cancer patients who were assessed (stage II, n = 10; stage IV, n = 7). (D) In a cohort of 41 patients with
breast cancer (stage I, n = 20; stage II, n = 12; and stage IV, n = 9), the percentage and intensity of expression of CD40 within the blood DC compartment
(encompassing DC and DR+IC) were analyzed and plotted. The normal reference range from healthy donors (n = 12) is indicated as shaded areas. Means are
shown as horizontal lines, and error bars indicate SEM. Statistically significant differences are indicated (**P < .01; ***P < .001).
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(bacterial oligodeoxynucleotide; CpG ODN)—all known to
induce maturation of APC [27,29,32]. We analyzed 16 pa-
tients with breast cancer (stage II, n = 9; stage IV, n = 7) and
found that freshly isolated DC were phenotypically imma-
ture, expressing low levels of CD40, CD80, CD83, and CD86
(Figure 6). Similarly, DR+IC expressed low levels of CD80,
CD83, and CD86, although, as noted previously, expression
of CD40 was elevated in 40% to 50% of cells (Figure 6).
Interestingly, DR+IC responded weakly to inflammatory
mediators and pathogen-derived products. Expression of
HLA-DR (Table 1) and CD40 (Figure 6, A–D) was increased,
and a modest upregulation of CD83 and CD86 expression
was noted in response to CpG ODN (Figure 6D ) and occa-
sionally to poly I:C (Figure 6B). In contrast, DC responded
vigorously to all proinflammatory and pathogen-derived fac-
tors (Figure 6 and Table 1), upregulating the expression of all
costimulatory and activation markers (CD40, CD80, CD83,
CD86, and HLA-DR).
Lineage Composition
Finally, given that DR+IC lacked an expression of markers
associated with mature hematopoietic (CD3, CD14, CD19,
CD20, and CD56) and circulating stem (CD34) cells, lineage
composition of these cells was further evaluated (Table 2).
To obtain representative data, phenotypic analyses were
conducted in a cohort of 21 patients with breast cancer
(stage II, n = 17; stage IV, n = 4). It was found that variable
proportions of DR+IC expressed molecules associated with
DC [33], including HLA-DR (100%), CD2 (7%), CD4 (3%),
and CD1c (22%). Similarly, a consistent proportion of DR+IC
expressed some early B-cell markers such as CD79a,
SIgn, SIgE, and cytoplasmic Cm (14–20%); and early pro-
genitormarkers such asCD7, CD10, CD13, CD33, andCD71
(3–15%). Less than 5% of DR+IC expressed markers for the
polymorphonuclear (PMN) or erythroid lineages such as
MPO, CD15, or CD235a; and 5% to 30% expressed integrins
such as CD11b, CD62L, CD41, and CD61. Altogether, these
data suggested that multiple small subpopulations of imma-
ture cells ascribed to different lineages coexist within the
DR+IC population.
Discussion
Despite the potential for tumor control, the immune system
often fails to prevent cancer progression. Substantial evidence
now indicates that defects in DC function have a crucial role in
this process. Hence, research into the biology of DC tumor
interactions has been the focus of much effort. Most knowl-
edge in this field has emerged from in vitro studies whereby
DC are generated from hematopoietic progenitors following
culture with cytokines [14,15,34,35]. However, cytokine-driven
activity of cultured DC is unlikely to reflect the functional status
of DC populations that are circulating in vivo. Therefore,
despite inherent methodological constraints, we evaluated
the blood DC compartment in a large cohort of patients with
various types of cancer. We report that, in these patients,
a population of HLA-DR+CD11cCD123 cells (DR+IC)
distinct from the recognized myeloid (CD11c+DC) and plas-
macytoid (CD123+DC) subtypes emerged as a significant pro-
portion of the DC compartment. Indeed, although DR+IC in
Figure 5. Antigen uptake and allostimulatory capacity. (A) Antigen uptake (FITC–TT, x axis) by DC and DR+IC from patients with cancer. Filled histograms indicate
uptake at 4jC (control), and empty histograms represent uptake at 37jC (test). Numbers indicate DMFI between test and control. (B) FITC–TT uptake by DC and
DR+IC was analyzed ex vivo (fresh) or following maturation with viral double-stranded RNA (poly I:C) or a combination of inflammatory cytokines (CC; TNF-a, IL-1,
IL-6, and PGE2). Uptake is expressed as DMFI (x axis) between test and control for each condition. Data shown are representative of five breast cancer patients
who were assessed (stage II). (C) Increasing numbers of DC and DR+IC purified from cancer patients were tested for their capacity to stimulate the proliferation of
allogeneic T-cells. Results shown correspond to two breast cancer patients (stage II) and are representative of five patients who were examined. (D) DC and DR+IC
purified from five cancer patients (stage II) were cultured with alloreactive T-cells and, after 5 days in culture, supernatants were analyzed for IFN-c content by
ELISA. Error bars correspond to SEM. Statistically significant differences between DC and DR+IC are indicated (*P < .05; ***P < .001).
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healthy donors represented 5% to 15% of LinHLA-DR+ cells,
it accounted for a significantly larger proportion in patients with
cancer (30–65%). Moreover, the relative proportion of DR+IC
in the circulation increased with advancing disease. Although
patients with locally limited breast cancer (stages I and II) had
twice the normal number, patients with advanced breast
cancer (stage IV) had a four-fold increase in DR+IC compared
to healthy donors.
One intriguing aspect of these findings is how cancer
progression could contribute to the selective accumulation of
immature cells in the circulation. It may be related to 1)
tumor-derived factors (granulocyte–macrophage colony-
stimulating factor) that promote the mobilization of precur-
sors from the bone marrow [36], or 2) tumor products (VEGF,
IL-6, M-CSF, gangliosides, prostanoids, and spermine) that
alter the differentiation of APC from their progenitors
[12–18]. Interestingly and supporting a role for tumor prod-
ucts in this process, we demonstrate a close correlation
between accumulation of immature cells in the blood and
tumor burden. Indeed, patients with metastatic disease
(stage IV) showed a larger number of DR+IC in the blood
than patients with nodal (stage II) or local disease (stage I).
In addition, in patients with fully resected malignant glioma,
the proportion of DR+IC in the circulation increased when
clinical and imaging evaluation demonstrated tumor progres-
sion. These results confirmed that the presence of DR+IC
within the blood DC compartment was associated with tumor
status and correlated with clinical behavior of the disease.
It is also tempting to speculate that, although the systemic
accumulation of immature cells could facilitate generalized
immune dysfunction as a late event, immature APC present
at the tumor site or lymphoid organs could play a role at an
earlier phase in tumor progression. Indeed, in patients
with head and neck squamous cell carcinoma, tumor infiltra-
tion with immature cells has been correlated with increased
rate of recurrence and metastases [37]. In our hands, how-
ever, the direct identification of DR+IC in tumor stroma has
remained difficult due to their lack of specific markers and
Table 1. Response to Proinflammatory and Pathogen-Derived Factorsy.
CC LPS Poly I:C CpG ODN
DC DR+IC DC DR+IC DC DR+IC DC DR+IC
CD40 351.9 ± 52.3** 82.4 ± 8.7** 344.4 ± 45.6** 122.0 ± 12.9** 175.6 ± 76.5** 57.9 ± 28.4** 218.3 ± 21.5 93.9 ± 33.3
CD80 17.3 ± 4.6** 0.6 ± 1.4** 34.7 ± 8.3** 4.4 ± 1.5** 22.6 ± 6.6** 3.5 ± 0.8** 10.0 ± 1.7 3.7 ± 3.3
CD83 65.2 ± 12.9** 9.14 ± 2.8** 40.9 ± 5.0*** 10.0 ± 2.3*** 20.3 ± 9.2** 6.4 ± 1.9** 77.9 ± 13.2* 24.3 ± 16.1*
CD86 729.51 ± 100.*** 314.5 ± 6.3*** 703.6 ± 85.6*** 22.9 ± 10.6*** 348.7 ± 159.5* 21.8 ± 5.3* 477.2 ± 32.9*** 3.6 ± 1.6***
HLA-DR 1046.5 ± 20.6* 273.9 ± 47.3* 1044.1 ± 56.7* 168.9 ± 60.7* 458.0 ± 70.8** 135.8 ± 29.0** 663.6 ± 209.5 297.5 ± 120.7
yPhenotypic maturation of DC and DR+IC was analyzed in PBMC following incubation with a combination of proinflammatory cytokines (TNF-a, IL-1b, IL-6, and
PGE2; CC) or pathogen-derived factors, including ligands for TLR4 (LPS), TLR3 (poly I:C), and TLR9 (CpG ODN). Data were collected from 16 patients with breast
cancer (stage II, n = 9; stage IV, n = 7). The magnitude of the response is expressed as DMFI (MFI of stimulated cells  MFI of unstimulated cells) ± SEM.
Statistically significant differences between DC and DR+IC are indicated.
*P < .05.
**P < .01.
***P < .001.
Figure 6. Response to proinflammatory and pathogen-derived factors. Phenotypic maturation was evaluated by assessing the expression of CD40, CD80, CD83,
and CD86 (x axis) on DC and DR+IC ( y axis) following incubation with (A) a combination of proinflammatory cytokines TNF-a, IL-1, IL-6, and PGE2 (CC); (B) viral
double-stranded RNA (poly I:C); (C) LPS; or (D) bacterial oligodeoxynucleotide (CpG-ODN). Filled histograms indicate expressions on unstimulated cells and
empty histograms following stimulation. Data shown are from two breast cancer patients (stage II) and are representative of 16 patients who were assessed
(stage II, n = 9; stage IV, n = 7).
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heterogeneity (unpublished data). Nevertheless, purification
and characterization of DR+IC were possible from the periph-
eral blood. Phenotypic characterization revealed minimal
expression of CD80 and CD83, moderate levels of CD86,
and high expression of CD40 and HLA-DR. Furthermore,
100% of DR+IC were MHC-I–positive, and 20% expressed
CD1c. All these molecules are involved in APC–T-cell inter-
actions, costimulation, and antigen presentation. Because
these data suggested that DR+IC could potentially perform as
APC, we assessed their capacity to 1) capture antigens, 2)
stimulate T-cell proliferation/IFN-g secretion, and 3) mature
in vitro on stimulation. Different types of stimuli or ‘‘danger sig-
nals,’’ including inflammatory cytokines, as well as ligands
for toll-like receptors 4 (LPS), 3 (poly I:C), and 9 (CpG ODN),
were tested. We found that, compared to DC, DR+IC had
lower antigen capture, presentation, and phenotypic matura-
tion in response to these inflammatory mediators. It may be
suggested that this nonresponsiveness could be due to
limited expression of cytokine or toll-like receptors. However,
upregulation in HLA-DR and CD40 expression was evident
with all stimuli (Table 1). Similarly, elevated expression of
CD83 and CD86 was noticeable in response to poly I:C and
CpG ODN, suggesting that DR+IC could respond, at least to
someextent, to inflammatorymediators. It may be that DR+IC
are functionally impaired due to an effect of the tumor. In this
regard, tumor-derived factors have been shown to induce
abnormal intracellular signaling (STAT-3 and NFnB) in APC
progenitors, thus hampering their differentiation and function
[38,39]. Alternatively, it could be related to the fact that most
DR+IC are represented by immature cells at early stages of
differentiation. The latter is more likely the case because
stimulation with CD40 ligation induces DR+IC differentiation/
maturation, as shown in an accompanying paper.1
Wealso confirmed the immaturity of DR+IC bymorphology
and phenotypic analyses. In contrast to DC, DR+IC were
small cells with short projections, poorly developed organella,
and largely condensed chromatin in the nucleus. Similarly,
lineage characterization suggested that multiple subpopula-
tions of immature cells were present. In accordance with
these results, it has been reported that disease progression in
cancer patients is associated with reduction of DC numbers
and the appearance of a large number of immature macro-
phages, granulocytes, DC, and precursors of the myelo/
monocytic lineage in the peripheral blood [11,36,40]. Other
studies indicate that accumulation of immature cells is not
only an indicator for tumor progression but may also promote
immune suppression. For instance, in patients with head and
neck, lung, and breast cancers, immature cells have been
shown to suppress responses to recall antigens and to in-
hibit antigen-specific immunity [40,41]. In contrast to those
studies, the DR+IC described here express HLA-DR and
other molecules associated with antigen presentation (CD86,
CD1c, and CD40), and capture and present antigens, sug-
gesting a role as inefficient APC rather than cells with suppres-
sive function. This assumption is further supported by the
finding that DR+IC do not inhibit T-cell proliferation in either al-
logeneic or antigen-specific manner when competent DC are
present, as described in our accompanying paper.
Interestingly, in contrast to the expression of HLA-DR,
CD86, and CD1c, the expression of CD40 was significantly
higher in DR+IC (51.0 ± 8.9%) when compared to DC (13.0 ±
5.5%). It has been demonstrated that CD40 ligation on DC
increases their resistance to tumor-induced apoptosis [42].
In an accompanying paper, we show that DR+IC’s expres-
sion of CD40 renders them exquisitely sensitive to signal-
ing through this pathway. Moreover, DR+IC demonstrate
Table 2. Phenotypic Characterization of DR+IC*
Names Definition/Function % Positive
Lineage markers
CD3 T-cell, TCR signaling V1
CD14 Monocyte, LPS recognition V1
CD19 B-cell, signal transduction V1
CD20 B-cell, activation V1
CD56 NK cell, adhesion V1
CD34 Progenitor, adhesion V1
DC markers
HLA-DR MHC-II 100
HLA-ABC MHC-I 100
CD11c Integrin, binds fibrinogen V1
CD2 Costimulation 7.2 ± 0.9
CD4 MHC-II coreceptor 2.9 ± 0.7
CD1c MHC-I – like molecule 21.5 ± 3.4
CD123 IL-3 receptor a chain V1
BDCA2 Type II C-type lectin V1
BDCA3 Type II C-type lectin V1
BDCA4 Type II C-type lectin 1.2 ± 0.7
DC-SIGN Type II C-type lectin 2.3 ± 1.9
Costimulatory molecules
CD40 Activation, binds CD40L 47.1 ± 6.2
CD80 Binds CD28 V1
CD83 Activation marker V1
CD86 Binds CD28 12.5 ± 3.0
Adhesion molecules
CD11b Integrin, binds ECM 23.6 ± 2.6
CD62L L-selectin, leukocyte tethering 27.0 ± 1.2
CD41 Integrin, binds fibrinogen 5.5 ± 0.7
CD61 Integrin, binds ECM 13.0 ± 4.3
PMN markers
Cytoplasmic MPO Enzymatic degradation 4.3 ± 0.6
CD15 Adhesion V1
Erythroid marker
CD235a, glycophorin A Anion transport 5.0 ± 2.8
Early B-cell markers
Cytoplasmic CD79a Signal transduction 20.0 ± 3.7
Igk Immunoglobulin light chain 14.4 ± 4.1
Igk Immunoglobulin light chain 20.0 ± 2.0
Cytoplasmic Cm Immunoglobulin M heavy chain 14.0 ± 9.2
Precursor markers
CD7 Lymphoid, costimulation 4.6 ± 0.7
CD10 Lymphoid, enzymatic activity 3.0 ± 1.0
CD13 Myeloid, metalloproteinase 4.5 ± 1.2
CD33 Myeloid, metalloproteinase 5.7 ± 1.7
CD71 Transferrin receptor 15.0 ± 3.8
*Phenotype of DR+IC in PBMC ex vivo. Data were collected from a cohort of
21 patients with breast cancer (stage II, n = 17; stage IV, n = 4). Values
indicate the proportion of DR+IC that are positive for each marker.
1HLA-DR+ immature cells exhibit reduced APC function but respond to CD40 stimulation.
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resistance to tumor-induced apoptosis. Thus, accumulation
of CD40+ immature cells probably represents accumulation
of cells resistant to the apoptotic effect of the tumor, and not
merely mobilization of progenitors from the bone marrow. In
this context, tumors may produce numerous suppressive
factors that induce a significant decline in the numbers of
CD11c+DC and CD123+DC (by altered differentiation or
apoptosis) with the concurrent accumulation of immature
cells (by recruitment or resistance to apoptosis), thus dis-
placing competent APC and favoring tumor evasion [21].
The findings reported here are relevant due to the large
effort devoted to harnessing blood DC for the immunotherapy
of cancer. In fact, blood DC have already been used for
vaccination in patients with multiple myeloma, albeit demon-
strating limited induction of tumor-specific immunity [43].
Similarly, preclinical studies have demonstrated that, al-
though DC generated in vitro from progenitors purified from
cancer patients are capable of stimulating T-cell responses,
blood DC isolated from the same patients are deficient in
their APC capacity [8,13]. Our study indicates that the defec-
tive function of circulating DC could, at least in part, be the
result of decreased frequency of competent DC and accu-
mulation of immature cells with poor APC function rather than
suppressive function. As demonstrated in our accompanying
paper (HLA-DR+ Immature Cells Exhibit Reduced Antigen-
Presenting Cell Function But Respond to CD40 Stimulation),
when T-cells primed with DR+IC were compared with T-cells
primed with DC, a different activation ‘‘pattern,’’ as assessed
by the expression of activation markers and cytokines, was
noted. Indeed, a smaller proportion of T-cells expressed
activation markers that were upregulated following adequate
T-cell activation, and Th2 bias in cytokine secretion was
detected. We propose that the significant accumulation of
immature cells (DR+IC) with poor APC function could con-
tribute to tumor immune evasion by displacing competent DC,
presenting antigens inadequately and inducing Th2 bias, thus
failing to generate effective antitumor responses.
In summary, we document the significant accumulation of
a novel population of cells within the blood DC compartment
of patients with cancer. This population exhibits heteroge-
neous and immature phenotype, limited response to ‘‘danger
signals,’’ and poor APC function. Increased numbers of these
cells closely correlate with disease stage and tumor progres-
sion. It is possible that the accumulation of these cells could
be associated with decreased immune function and com-
promised clinical status in patients with cancer. Our data
should also be taken into account when assessing immune
competence (i.e., DC enumeration/characterization in pa-
tients with cancer), and they necessitate prudence when
using the peripheral blood DC compartment as a source of
cells for DC-based cancer immunotherapy protocols.
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